AtriCure, Inc. (ATRC)
USD 30.25
(-3.97%)
USD 30.25
(-3.97%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 327.05 Million USD | 13.83% |
| 2022 | 288.6 Million USD | 14.0% |
| 2021 | 253.15 Million USD | 30.8% |
| 2020 | 193.54 Million USD | -4.87% |
| 2019 | 203.45 Million USD | 23.87% |
| 2018 | 164.24 Million USD | 8.67% |
| 2017 | 151.14 Million USD | 6.26% |
| 2016 | 142.23 Million USD | 18.93% |
| 2015 | 119.59 Million USD | 29.84% |
| 2014 | 92.11 Million USD | 30.74% |
| 2013 | 70.45 Million USD | 23.15% |
| 2012 | 57.21 Million USD | 10.6% |
| 2011 | 51.72 Million USD | 6.48% |
| 2010 | 48.57 Million USD | -3.77% |
| 2009 | 50.48 Million USD | -4.81% |
| 2008 | 53.03 Million USD | 4.51% |
| 2007 | 50.73 Million USD | 11.8% |
| 2006 | 45.38 Million USD | 34.66% |
| 2005 | 33.7 Million USD | 71.88% |
| 2004 | 19.6 Million USD | 86.09% |
| 2003 | 10.53 Million USD | 56.17% |
| 2002 | 6.74 Million USD | 114.05% |
| 2001 | 3.15 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 91.44 Million USD | 4.22% |
| 2024 Q2 | 93.25 Million USD | 1.97% |
| 2024 Q3 | 94.19 Million USD | 1.01% |
| 2023 Q1 | 75.39 Million USD | 8.87% |
| 2023 Q4 | 87.74 Million USD | 7.06% |
| 2023 FY | 328.51 Million USD | 13.83% |
| 2023 Q2 | 81.22 Million USD | 7.73% |
| 2023 Q3 | 81.95 Million USD | 0.91% |
| 2022 Q2 | 77.17 Million USD | 10.66% |
| 2022 Q3 | 72.43 Million USD | -6.15% |
| 2022 Q4 | 69.24 Million USD | -4.4% |
| 2022 FY | 288.6 Million USD | 14.0% |
| 2022 Q1 | 69.74 Million USD | 3.3% |
| 2021 Q3 | 61.15 Million USD | -11.57% |
| 2021 Q1 | 60.42 Million USD | 0.81% |
| 2021 Q2 | 69.15 Million USD | 14.45% |
| 2021 FY | 253.15 Million USD | 30.8% |
| 2021 Q4 | 67.51 Million USD | 10.4% |
| 2020 Q4 | 59.94 Million USD | 35.23% |
| 2020 FY | 193.54 Million USD | -4.87% |
| 2020 Q1 | 54.33 Million USD | -9.59% |
| 2020 Q2 | 34.93 Million USD | -35.7% |
| 2020 Q3 | 44.32 Million USD | 26.86% |
| 2019 FY | 203.45 Million USD | 23.87% |
| 2019 Q2 | 47.73 Million USD | 5.62% |
| 2019 Q3 | 50.43 Million USD | 5.66% |
| 2019 Q4 | 60.1 Million USD | 19.17% |
| 2019 Q1 | 45.19 Million USD | 9.69% |
| 2018 Q2 | 37.12 Million USD | -15.51% |
| 2018 FY | 164.24 Million USD | 8.67% |
| 2018 Q4 | 41.19 Million USD | -1.9% |
| 2018 Q3 | 41.99 Million USD | 13.13% |
| 2018 Q1 | 43.93 Million USD | 26.18% |
| 2017 Q2 | 38.9 Million USD | -1.87% |
| 2017 Q1 | 39.65 Million USD | 8.36% |
| 2017 FY | 151.14 Million USD | 6.26% |
| 2017 Q4 | 34.81 Million USD | -7.8% |
| 2017 Q3 | 37.76 Million USD | -2.94% |
| 2016 Q3 | 33.75 Million USD | -7.65% |
| 2016 Q1 | 35.33 Million USD | -2.33% |
| 2016 FY | 142.23 Million USD | 18.93% |
| 2016 Q2 | 36.55 Million USD | 3.46% |
| 2016 Q4 | 36.59 Million USD | 8.4% |
| 2015 Q2 | 27.93 Million USD | 3.93% |
| 2015 FY | 119.59 Million USD | 29.84% |
| 2015 Q3 | 28.6 Million USD | 2.39% |
| 2015 Q4 | 36.17 Million USD | 26.46% |
| 2015 Q1 | 26.87 Million USD | 6.67% |
| 2014 Q1 | 25.58 Million USD | 24.75% |
| 2014 FY | 92.11 Million USD | 30.74% |
| 2014 Q2 | 21.63 Million USD | -15.43% |
| 2014 Q4 | 25.19 Million USD | 27.95% |
| 2014 Q3 | 19.69 Million USD | -8.96% |
| 2013 Q2 | 16.76 Million USD | 5.51% |
| 2013 Q1 | 15.88 Million USD | 6.95% |
| 2013 Q4 | 20.5 Million USD | 18.54% |
| 2013 Q3 | 17.29 Million USD | 3.2% |
| 2013 FY | 70.45 Million USD | 23.15% |
| 2012 Q3 | 14.07 Million USD | 0.33% |
| 2012 Q4 | 14.85 Million USD | 5.51% |
| 2012 Q2 | 14.03 Million USD | -1.52% |
| 2012 FY | 57.21 Million USD | 10.6% |
| 2012 Q1 | 14.24 Million USD | 6.05% |
| 2011 Q1 | 12.96 Million USD | 3.37% |
| 2011 Q4 | 13.43 Million USD | 9.44% |
| 2011 FY | 51.72 Million USD | 6.48% |
| 2011 Q3 | 12.27 Million USD | -5.92% |
| 2011 Q2 | 13.04 Million USD | 0.63% |
| 2010 Q4 | 12.54 Million USD | 4.49% |
| 2010 Q2 | 11.66 Million USD | -5.72% |
| 2010 Q3 | 12 Million USD | 2.94% |
| 2010 Q1 | 12.36 Million USD | -1.0% |
| 2010 FY | 48.57 Million USD | -3.77% |
| 2009 Q1 | 11.84 Million USD | -4.61% |
| 2009 Q4 | 12.49 Million USD | -13.44% |
| 2009 Q3 | 14.43 Million USD | 23.34% |
| 2009 Q2 | 11.7 Million USD | -1.23% |
| 2009 FY | 50.48 Million USD | -4.81% |
| 2008 Q3 | 13.22 Million USD | 0.27% |
| 2008 FY | 53.03 Million USD | 4.51% |
| 2008 Q1 | 14.19 Million USD | 16.74% |
| 2008 Q2 | 13.18 Million USD | -7.09% |
| 2008 Q4 | 12.42 Million USD | -6.06% |
| 2007 Q1 | 13.41 Million USD | 5.62% |
| 2007 FY | 50.73 Million USD | 11.8% |
| 2007 Q2 | 12.96 Million USD | -3.34% |
| 2007 Q4 | 12.15 Million USD | -0.35% |
| 2007 Q3 | 12.2 Million USD | -5.88% |
| 2006 FY | 45.38 Million USD | 34.66% |
| 2006 Q1 | 10.4 Million USD | -2.85% |
| 2006 Q2 | 11.41 Million USD | 9.71% |
| 2006 Q3 | 10.86 Million USD | -4.85% |
| 2006 Q4 | 12.69 Million USD | 16.89% |
| 2005 Q3 | 8.92 Million USD | 25.41% |
| 2005 Q4 | 10.71 Million USD | 20.07% |
| 2005 Q1 | 6.98 Million USD | 4.03% |
| 2005 FY | 33.7 Million USD | 71.88% |
| 2005 Q2 | 7.11 Million USD | 1.78% |
| 2004 FY | 19.6 Million USD | 86.09% |
| 2004 Q4 | 6.71 Million USD | 33.09% |
| 2004 Q2 | 3.96 Million USD | 0.0% |
| 2004 Q3 | 5.04 Million USD | 27.37% |
| 2003 FY | 10.53 Million USD | 56.17% |
| 2002 FY | 6.74 Million USD | 114.05% |
| 2001 FY | 3.15 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 104.27 Million USD | -213.66% |
| AngioDynamics, Inc. | 252.41 Million USD | -29.569% |
| Avinger, Inc. | 18.63 Million USD | -1654.764% |
| Azenta, Inc. | 336.26 Million USD | 2.74% |
| BioLife Solutions, Inc. | 117.57 Million USD | -178.161% |
| The Cooper Companies, Inc. | 1.82 Billion USD | 82.077% |
| Daxor Corporation | 1.28 Million USD | -25440.739% |
| Ekso Bionics Holdings, Inc. | 24.19 Million USD | -1251.961% |
| Femasys Inc. | 15.2 Million USD | -2051.62% |
| GlucoTrack, Inc. | 7.1 Million USD | -4503.787% |
| Harvard Bioscience, Inc. | 58.58 Million USD | -458.292% |
| Hologic, Inc. | 1.34 Billion USD | 75.687% |
| ICU Medical, Inc. | 717.04 Million USD | 54.389% |
| Intuitive Surgical, Inc. | 2.96 Billion USD | 88.961% |
| KORU Medical Systems, Inc. | 26.1 Million USD | -1152.699% |
| LeMaitre Vascular, Inc. | 90.33 Million USD | -262.037% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 274176.712% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 274176.712% |
| Masimo Corporation | 867 Million USD | 62.278% |
| Microbot Medical Inc. | 9.85 Million USD | -3218.65% |
| Meihua International Medical Technologies Co., Ltd. | 18.42 Million USD | -1675.526% |
| Merit Medical Systems, Inc. | 459.92 Million USD | 28.89% |
| Nephros, Inc. | 9.78 Million USD | -3242.733% |
| NovoCure Limited | 613.92 Million USD | 46.728% |
| NEXGEL, Inc. | 4.09 Million USD | -7884.692% |
| NEXGEL, Inc. | 4.09 Million USD | -7884.692% |
| Singular Genomics Systems, Inc. | 102.24 Million USD | -219.878% |
| OraSure Technologies, Inc. | 125.34 Million USD | -160.928% |
| Pro-Dex, Inc. | 7.37 Million USD | -4332.814% |
| Pulse Biosciences, Inc. | 43.57 Million USD | -650.569% |
| Predictive Oncology Inc. | 15.22 Million USD | -2047.492% |
| Precision Optics Corporation, Inc. | 8.52 Million USD | -3737.7% |
| QuidelOrtho Corporation | 1.35 Billion USD | 75.869% |
| Repligen Corporation | 261.12 Million USD | -25.249% |
| Sanara MedTech Inc. | 61.12 Million USD | -435.037% |
| STAAR Surgical Company | 224.55 Million USD | -45.646% |
| Sharps Technology, Inc. | 10.12 Million USD | -3129.627% |
| Utah Medical Products, Inc. | 13.26 Million USD | -2366.277% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 81.77% |
| Jin Medical International Ltd. | 3.91 Million USD | -8248.36% |